Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process

Adhoute, Xavier; Pénaranda, Guillaume; Naudé, Sébastien; Raoul, Jean‐Luc; Perrier, H.; Bayle, Olivier; Monnet, O.; Beaurain, Patrick; Bazin, Christophe; Pol, Bernard; Folgoc, Gaëlle Le; Castellani, Paul; Bronowicki, Jean Pierre; Bourlière, Marc

doi:10.1016/j.jhep.2014.11.014

Cited by 144 publications

(150 citation statements)

References 35 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Для отбора пациентов для продолжения ТАХЭ предла-гается две несложных в обращении шкалы, полученные с использованием регрессионной модели: «Оценка для по-вторного лечения ТАХЭ» (The Assessment for Retreatment with ТАСЕ) -ART, и шкала ABCR [64,65]. Шкала ART име-ет наибольшую оценку в баллах при повышении уровня ASAT (4 балла), а наименьшую -при выраженном ради-ологическом ответе (1 балл).…”

Section: после первой тахэunclassified

“…При значении > 2 баллов не рекомендуется продолжать ТАХЭ. Однако попытки привязать данные шкалы для оценки по-сле второго или третьего курса ТАХЭ не увенчались успе-хом [63,65]. После повторной ТАХЭ показатели шкалы ART не коррелируют с выживаемостью.…”

Section: после первой тахэunclassified

See 1 more Smart Citation

The problem of current classications of the hepatocellular carcinoma. Analytical review

Ротин¹,

Мороз²

2017

Zlokač. opuholi

View full text Add to dashboard Cite

Section: после первой тахэunclassified

The problem of current classications of the hepatocellular carcinoma. Analytical review

Ротин¹,

Мороз²

2017

Zlokač. opuholi

View full text Add to dashboard Cite

“…After the first TACE: Two scores easy to calculate were proposed to improve the selection of patients before repeating the treatment: The Assessment for Retreatment with TACE (ART) and the ABCR scores, both defined using regression models [62,63] . The ART score associates its higher coefficient with a possible increase in ASAT levels (4 points), the lower being associated with the radiological response (1 point).…”

Section: Before the First Treatmentmentioning

confidence: 99%

“…Both scores are usable after the second treatment. From a European multicenter cohort, the ART score calculated before the second or the third TACE failed to orientate the treatment option for all the patients [61,63] . If, unlike the ABCR, it did discriminate two different prognosis subgroups, the evolution of the ART score was not correlated with survival.…”

Section: Before the First Treatmentmentioning

confidence: 99%

Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments

Adhoute¹,

Pénaranda²,

Raoul³

et al. 2016

WJH

Self Cite

View full text Add to dashboard Cite

“…Based on this concept of intractable progression, various indexes have been recently generated, aimed to objectively decide when to interrupt TACE because of inefficiency or uselessness. Most of these indexes consider radiological response and liver function worsening as the main parameters for assessing TACE failure (77,79). Unfortunately, these indexes have not been externally validated and many of them are derived from cohorts of patients who initially were bad candidates for TACE.…”

Section: Improvements In the Treatment Of Intermediate-advanced Hccmentioning

confidence: 99%

New challenges in clinical research on hepatocellular carcinoma

Díaz-González¹,

Forner²,

C³

et al. 2015

Rev Esp Enferm Dig

View full text Add to dashboard Cite

This is an updated review of screening, early diagnosis and treatment of hepatocellular carcinoma, focusing on the advancements occurred in the last years and highlighting the challenges in clinical research.Hepatocellular carcinoma (HCC) is nowadays the sixth most frequent cancer worldwide with up to 740,000 new cases diagnosed each year, and it is the third most prevalent cause of cancer-relateddeath worldwide (1). This neoplasm usually appears linked to an underlying liver disease, being one of the most relevant causes of death in patients diagnosed of liver cirrhosis (2,3). In the last years, important advancements in terms of diagnosis, staging and treatment of HCC, improving the management and outcome of the disease, have been made (4-7). Despite the fact that these improvements have absolutely changed natural history of HCC, there are several areas that still need further advancements.The aim of this document is to discuss some controversial aspects, which in our opinion constitute real challenges in clinical research of HCC.Key words: Hepatocellular carcinoma. Hepatic oncology. Sorafenib. Transarterial chemoembolization. AFP. IMPROVING EARLY DIAGNOSISFrom the basis that the only possibility to offer and apply treatments with curative intention is being able to diagnose HCC at early stages, when there are not cancer related symptoms. Since this option is only feasible if screening is performed in population at risk, scientific guidelines recommend performing abdominal ultrasonography (US) in every patient with liver cirrhosis. Despite the recommendation of HCC screening by the Spanish guidelines (4), one registry study performed in Spain which included 62 centers and 705 patients diagnosed of HCC within a period of time of 4 months showed that just 47% of HCC patients were diagnosed in the setting of surveillance and less than a half were diagnosed at early stage (8).This data shows that early diagnosis, a key issue to be able to significantly reduce HCC-related mortality, is one of the most relevant issues that deserve further efforts from scientific community. Aiming to evaluate which were the causes of screening program fail in the United States of America, Singal et al. evaluated 1,005 patients included in the HALT-C prospective study. A third part of patients did not adhere to an adequate screening program and, in 70% of cases that were diagnosed at an advanced stage, the main reason was the absence of detection in US (9).With the aim of improving detection rate, it is crucial to establish formative programs in order to certify the capability of being able to carry on this activity and it is necessary to use up-to-date ultrasonography scans in order to perform an optimal liver exploration. Tumor markers could be a useful tool to overcome theoretical limitations of US: its evaluation is not subjective, does not depend on the operator and it may be reproducible, as well as it is relatively cheap and a tool easy to access in areas with low monetary income. Regrettably, different tumor markers ev...

show abstract

Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process

Cited by 144 publications

References 35 publications

The problem of current classications of the hepatocellular carcinoma. Analytical review

The problem of current classications of the hepatocellular carcinoma. Analytical review

Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments

New challenges in clinical research on hepatocellular carcinoma

Contact Info

Product

Resources

About